BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Aug 29, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Veltuzumab: Phase II started

Immunomedics disclosed in its fiscal year 2011 earnings ending June 30 that partner Nycomed began the double-blind, placebo-controlled, international Phase II VELVET trial to evaluate 80, 160 and 320 mg subcutaneous veltuzumab once weekly for 4 weeks as an add-on to methotrexate in...

Read the full 192 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >